{
    "clinical_study": {
        "@rank": "51819", 
        "arm_group": {
            "arm_group_label": "Collection of CSF", 
            "description": "Those with Alzheimer's disease\nThose with non-Alzheimer's disease dementia\nHealthy elderly volunteers"
        }, 
        "biospec_descr": {
            "textblock": "Blood, urine and cerebral spinal fluid."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "To establish a cutoff value using a ratio of CSF tau to A\u03b242 (tau/A\u03b242) for distinguishing\n      patients wth mild to moderate Alzheimer's disease (AD) from health elderly control subjects.\n       The investigators hypothesize that a cutoff can be found that has at least 80% sensitivity\n      and 60% specificity."
        }, 
        "brief_title": "Cerebrospinal Fluid (CSF) Biomarkers Alzheimer's Disease (AD) and Non-AD Dementias", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Alzheimer's Disease", 
            "Dementias"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Alzheimer Disease", 
                "Dementia"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will enroll 50 AD subjects, 50 normal controls and approximately 20 subjects with\n      non-AD dementia. There will be 2 visits (up to 30 days apart), and a telephone follow-up\n      visit.\n\n      This protocol does not include treatment of subjects. Lumbar puncture and phlebotomy are\n      routine clinical tasks and are associated with a low level of risk. All adverse events will\n      be documented and reviewed by the PI."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Each subject must be \u2265 55 to \u2264 85 years of age.\n\n          -  Each subject must be able to read at a 6th grade level, as determined by the\n             investigator, and must have a history of academic achievement and/or employment\n             sufficient to exclude mental retardation.\n\n          -  Each subject must have results of clinical laboratory tests, a physical examination,\n             vital signs within normal limits or clinically acceptable to the investigator within\n             28 days prior to enrollment.\n\n          -  Each subject (or legal representative) must sign the informed consent form after the\n             scope and nature of the investigation have been explained to them, and before\n             screening assessments.\n\n        Additional Inclusion Criteria for Normal Controls:\n\n          -  Must have a global Clinical Dementia Rating (CDR) score of 0.\n\n          -  Must have a Mini-Mental State Examination (MMSE) score \u2265 28.\n\n          -  Must have a Z-score \u2265 -1.0 in each cognitive domain of memory (including delayed\n             recall), language, executive function and attention, and visuoconstruction with\n             neuropsychological tests of choice and adjustment for age, gender, and education\n             level if indicated.\n\n        Additional Inclusion Criteria for AD Subjects:\n\n          -  Must meet the criteria for a diagnosis of probable AD based on both\n\n               1. the National Institute of Neurological and Communicative Diseases and\n                  Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)\n                  criteria, and\n\n               2. the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text\n                  Revision (DSM IV TR) criteria for AD.\n\n          -  Must have an MMSE score \u2265 15 and \u2264 26.\n\n          -  Must have a clear history of cognitive and functional decline over at least one year\n             that is either\n\n               1. documented in medical records or\n\n               2. documented by history from an informant who knows the subject well.\n\n          -  Must have an MRI or CT scan that is consistent with a diagnosis of AD within 12\n             months prior to enrollment.\n\n        Exclusion Criteria for AD Subjects and Normal Controls\n\n          -  The subject has a Rosen modified Hachinski Ischemia Score > 4.\n\n          -  The subject has a known history of stroke.\n\n          -  The subject has evidence of a clinically relevant or unstable neurological or\n             psychiatric disorder (for AD subjects - other than AD).\n\n          -  The subject has a history of alcoholism or drug dependency/abuse within the last 5\n             years before enrollment.\n\n          -  The subject has an ongoing uncontrolled, clinically significant medical condition\n             such that, in the judgment of the investigator, a subject's participation in the\n             trial would pose a significant medical risk to the subject.\n\n          -  The subject has participated within the last two months in a clinical trial of a\n             novel therapeutic agent (e.g. bapineuzumab) or has ever been in a clinical trial of\n             an AD vaccine.\n\n          -  Pregnancy\n\n        Additional Inclusion and Exclusion Criteria for Subject with non-AD dementias\n\n          -  Standard clinical diagnostic criteria accepted by the field for non-AD dementias\n             should be used by the Institution."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "55 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Duke Memory Disorders Clinic"
            }
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01730430", 
            "org_study_id": "Pro00033660"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "non-AD dementias", 
            "healthy elderly controls"
        ], 
        "lastchanged_date": "April 18, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27705"
                }, 
                "name": "Duke Health Center at Morreene Road"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Investigation of Biomarkers of Disease State in Alzheimer's Disease and Non-AD Dementias", 
        "overall_official": {
            "affiliation": "Duke UMC", 
            "last_name": "James Burke, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "CSF will be collected in clinic and shipped frozen to Merck's Clinical Development Lab for testing.  Any remaining samples will be kept up to 20 years.", 
            "measure": "Ratio of CSF tau to A\u03b242 (tau/A\u03b242)", 
            "safety_issue": "No", 
            "time_frame": "CSF will be collected at Visit 1 (up to 30 days after the screening visit)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01730430"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}